Drugs / HS-10374
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07181343 | May → Jun 2025 | psoriasis | Hansoh BioMedical R&D Company | Completed | No outcome recorded |
| Phase 1 | NCT06033742 | Nov 2021 → Mar 2023 | psoriasis | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06926582 | Apr 2025 → Jul 2026 overdue | psoriasis | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06176508 | Feb 2024 → Apr 2026 overdue | psoriatic arthritis | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 2 | NCT06077331 | Sep 2023 → Jul 2024 | psoriasis | Hansoh BioMedical R&D Company | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06672393 | Nov 2024 → Oct 2025 overdue | psoriasis | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10374 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06672393 ↗ |
| Route | Oral | “Single or multiple dosing of HS-10374 orally in a fasting state” NCT06033742 ↗ |